HNSCC treatment has seen a paradigm shift with the introduction of cancer immunotherapy, with the targeting of immune checkpoints such as the PD-1/PD-L1 interaction showing the greatest clinical activity4–6. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.